The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update
| Autor: | I. J. Ansotegui, Bruce L. Zuraw, Stephen Betschel, Marcus Maurer, Alexander Nast, Paul Potter, Marc A. Riedl, Inmaculada Martinez-Saguer, Mario Sánchez-Borges, Henriette Farkas, Ruby Pawankar, Emel Aygören-Pürsün, Bruce Ritchie, Constance H. Katelaris, Hilary Longhurst, Lanny J. Rosenwasser, W. R. Lumry, Timothy J. Craig, R. Lockey, Markus Magerl, Yuxiang Zhi, Michihiro Hide, Dumitru Moldovan, Tom Bowen, Konrad Bork, H. Balle Boysen, Anete Sevciovic Grumach |
|---|---|
| Přispěvatelé: | Department of Medicine, Faculty of Health Sciences, Apollo - University of Cambridge Repository |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Aftercare 32 Biomedical and Clinical Sciences Lanadelumab C1-inhibitor Disease Guideline Recommendations 0302 clinical medicine Pregnancy Diagnosis Immunology and Allergy 030212 general & internal medicine Precision Medicine Child Hereditary angioedema Consensus conference Self-administration Management GRADE Female Complement C1 Inhibitor Protein Quality of life Adult Pulmonary and Respiratory Medicine medicine.medical_specialty What treatment Consensus Adolescent Health Planning Guidelines Immunology MEDLINE Dysfunctional family 7.3 Management and decision making Young Adult 03 medical and health sciences Rare Diseases Quality of life (healthcare) Clinical Research Terminology as Topic Individualized therapy medicine Humans Lactation Final version Prophylaxis business.industry Prevention Angioedemas Hereditary Precision medicine medicine.disease 3211 Oncology and Carcinogenesis 030228 respiratory system Family medicine Therapy business 7 Management of diseases and conditions |
| Zdroj: | World Allergy Organization Journal |
| DOI: | 10.17863/cam.21827 |
| Popis: | Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|